ES2807026T3 - Método para proporcionar linfocitos T específicos de tumor - Google Patents

Método para proporcionar linfocitos T específicos de tumor Download PDF

Info

Publication number
ES2807026T3
ES2807026T3 ES18167345T ES18167345T ES2807026T3 ES 2807026 T3 ES2807026 T3 ES 2807026T3 ES 18167345 T ES18167345 T ES 18167345T ES 18167345 T ES18167345 T ES 18167345T ES 2807026 T3 ES2807026 T3 ES 2807026T3
Authority
ES
Spain
Prior art keywords
tumor
specific
nucleic acid
lymphocyte
clonotypes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18167345T
Other languages
English (en)
Spanish (es)
Inventor
Rudolf Hammer
Steffen Hennig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HS DIAGNOMICS GmbH
Original Assignee
HS DIAGNOMICS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HS DIAGNOMICS GmbH filed Critical HS DIAGNOMICS GmbH
Application granted granted Critical
Publication of ES2807026T3 publication Critical patent/ES2807026T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
ES18167345T 2015-08-10 2016-08-10 Método para proporcionar linfocitos T específicos de tumor Active ES2807026T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15180383 2015-08-10
EP15202419 2015-12-23

Publications (1)

Publication Number Publication Date
ES2807026T3 true ES2807026T3 (es) 2021-02-19

Family

ID=56738102

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18167345T Active ES2807026T3 (es) 2015-08-10 2016-08-10 Método para proporcionar linfocitos T específicos de tumor
ES16753630.9T Active ES2679798T3 (es) 2015-08-10 2016-08-10 Método para proporcionar linfocitos T específicos de tumor

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16753630.9T Active ES2679798T3 (es) 2015-08-10 2016-08-10 Método para proporcionar linfocitos T específicos de tumor

Country Status (6)

Country Link
US (1) US20190255162A1 (https=)
EP (2) EP3180433B1 (https=)
JP (1) JP6815400B2 (https=)
DK (2) DK3372683T3 (https=)
ES (2) ES2807026T3 (https=)
WO (1) WO2017025564A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220112557A1 (en) * 2019-01-10 2022-04-14 Iovance Biotherapeutics, Inc. System and methods for monitoring adoptive cell therapy clonality and persistence
CN117794553A (zh) 2021-07-15 2024-03-29 勃林格殷格翰国际公司 鉴定共同肿瘤特异性t细胞受体和抗原
EP4426320A4 (en) * 2021-11-03 2025-11-05 Univ Delaware SYSTEM FOR ADMINISTRATING CELL-DERIVED MICROPARTICLES AND ITS USES
CN114530202A (zh) * 2021-12-20 2022-05-24 深圳泛因医学有限公司 鉴定抗原特异性tcr或bcr的方法及应用
WO2023232785A1 (en) 2022-05-30 2023-12-07 Hs Diagnomics Gmbh Common tumor-specific t cell receptors
EP4649952A1 (en) 2024-05-14 2025-11-19 HS Diagnomics GmbH Kras q16h specific t cell receptors and uses thereof
WO2025238079A1 (en) 2024-05-14 2025-11-20 Hs Diagnomics Gmbh Kras q16h specific t cell receptors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128153D0 (en) * 2001-11-23 2002-01-16 Bayer Ag Profiling of the immune gene repertoire
DE102004063339A1 (de) 2004-12-23 2006-07-06 Bayer Technology Services Gmbh Sonde zum Nachweis von Nukleinsäuren
EP2980225B1 (en) * 2012-04-20 2017-11-08 Alacris Theranostics GmbH Cdr sequence-specific enrichment of live immune cells
EP2746405B1 (en) 2012-12-23 2015-11-04 HS Diagnomics GmbH Methods and primer sets for high throughput PCR sequencing
CN106103711A (zh) * 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用

Also Published As

Publication number Publication date
EP3372683B1 (en) 2020-05-27
EP3180433B1 (en) 2018-04-18
JP2018525034A (ja) 2018-09-06
CA3030959A1 (en) 2017-02-16
ES2679798T3 (es) 2018-08-31
WO2017025564A1 (en) 2017-02-16
EP3372683A1 (en) 2018-09-12
DK3372683T3 (da) 2020-07-27
JP6815400B2 (ja) 2021-01-20
DK3180433T3 (en) 2018-07-30
EP3180433A1 (en) 2017-06-21
US20190255162A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
ES2807026T3 (es) Método para proporcionar linfocitos T específicos de tumor
US12509724B2 (en) High-throughput single-cell analysis combining proteomic and genomic information
CN108779488B (zh) 采用双探针邻近性连接系统的多重单分子rna可视化
US20240384259A1 (en) Method and kit for labeling nucleic acid molecules
AU2018281745B2 (en) Sample indexing for single cells
US20250354982A1 (en) Single cell secretome analysis
WO2021030627A1 (en) Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US20210180067A1 (en) Nucleic acid aptamers
WO2019129133A1 (zh) 一种获得单细胞mRNA序列的方法
WO2023230632A2 (en) Treatment and detection of cancers having a neural-like progenitor, squamoid/basaloid/mesenchymal, or classical phenotype
KR101641920B1 (ko) EpCAM에 특이적으로 결합하는 핵산 앱타머 및 이의 용도
CN110747275B (zh) 肿瘤细胞标记分子及其应用
KR20120060442A (ko) 위암 진단용 마커로서 ｔｆｆ2의 용도
US20240376543A1 (en) Method for providing tumour-specific t cells
CA3030959C (en) Method for providing tumour-specific t cells
RU2449016C2 (ru) Ген, вовлеченный в иммортализацию раковой клетки человека, и его применение
WO2025072917A1 (en) Barcoding intracellular reverse transcription enables high- throughput analysis of rna sequences
Yu et al. NMB+ CXCL13+ CD4+ T cells-derived neuromedin-B promotes neuropeptide S receptor 1 positive malignant cells senescence and malignancy
Bavli et al. CloneSeq: A Highly Sensitive Single-cell Analysis Platform for Comprehensive Characterization of Cells from 3D Culture
Jepson Single-cell microRNA sequencing of circulating tumour cells: a new tool for monitoring prostate cancer
EP4612318A1 (en) Bead-based single cell secretome analysis
WO2023179795A1 (zh) 一种快速且简便地获得正确配对tcr的方法以及获得的tcr
CN113795278A (zh) Rna适配体及其用途
Masibag Aptamer selection for targeting AXL protein receptor expressed on cells and human IgG FC fragment
HK40007814A (en) Oligonucleotide probes and uses thereof